Vanguard FTSE Global Small-Cap UCITS ETF Accun USD (NL:VSML) Price & Chart

Citi raised the firm’s price target on ATI (ATI) to $240 from $229 and keeps a Buy rating on the shares following the investor day. Citi views the event as

TD Cowen says ATI‘s (ATI) investor day slides, which outlined annual sales growth of 10%-12% through 2029, above the Street’s 9% estimate, and EBITDA margin of high-20% to low-30%, implies

Targets 2029 adjusted EBITDA Margin high-20s to low-30s percentage. Targets 2029 adjusted free cash flow roughly $1.25B. Targets 2029 percent of adjusted FCF returned over 75%. Guidance taken from investor

Oddo BHF downgraded TechnipFMC (FTI) to Underperform from Neutral with a $55 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

The company said, “Moderna’s (MRNA) strategy is built on an integrated mRNA platform combining mRNA science, delivery technologies and manufacturing capabilities. By developing modalities that share underlying technologies and processes,

The company said, “Manufacturing is a core component of Moderna’s (MRNA) integrated mRNA platform, supporting commercial vaccine supply, strategic partnerships and the potential launch of individualized cancer therapies. Manufacturing operations

Moderna (MRNA) outlined the next phase of growth at its 2026 Analyst Day, highlighting how more than a decade of investment in the Company’s mRNA platform has enabled the development

Moderna (MRNA) expects 2026 revenue growth of 15% to 25%, compared with the original outlook of up to 10%, and is on track to achieve approximately 10 percentage points of

Viatris (VTRS) is acquiring Pacira BioSciences (PCRX) in a deal expected to close soon, pending final closing conditions. Published first on TheFly – the ultimate source for real-time, market-moving breaking